Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Chronic-Phase
Conditions
Leukemia, Myeloid, Chronic-Phase
Trial Timeline
Jul 1, 2009 → Jan 1, 2017
NCT ID
NCT01827930About Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate is a phase 3 stage product being developed by Novartis for Leukemia, Myeloid, Chronic-Phase. The current trial status is terminated. This product is registered under clinical trial identifier NCT01827930. Target conditions include Leukemia, Myeloid, Chronic-Phase.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Chronic-Phase were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01827930 | Phase 3 | Terminated |
Competing Products
20 competing products in Leukemia, Myeloid, Chronic-Phase